GSK will pay $90 million to settle diabetes drug allegations

Share this article:
GlaxoSmithKline will pay a $90 million settlement to 38 states that claimed it unlawfully promoted its diabetes treatment Avandia (rosiglitazone). As a result of the settlement, GSK must change the way it promotes its diabetes drugs, including Avandia. However, the company did not admit to “any wrongdoing or liability of any kind.” The states charged that GSK did not report some Avandia safety data. They also said the drug manufacturer violated consumer protection laws when it misrepresented heart attack risk with the drug, as well as the safety of its use, alone or in combination with other drugs.

Share this article:

More in Products

Last day to enter McKnight's Tech Awards

Today is the final day to submit entries into the third annual McKnight's Excellence in Technology Awards.

AliMed offers three new fall management products

AliMed offers three new fall management products

AliMed is now offering the AliMed CordLess® Sensor Alarm and the AliMed Worry-Free Fall Alarm to help reduce the risk of accidental falls, and the HipShield® X-tra to help prevent ...

Diamond Wipes creates new wipes

Diamond Wipes creates new wipes

Diamond Wipes has announced an updated version of its Handyclean™ cleaning and sanitizing wipes.